Despite a restricted FDA label, Sarepta Therapeutics has seen early commercial success with its Duchenne muscular dystrophy (DMD) gene therapy Elevidys. This year, the company aims to dramatically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback